Form 4: Director Patrick Machado Increases Stake in Arcus Biosciences
Statement of Changes in Beneficial Ownership
Director Patrick Machado acquired 5,700 restricted stock units and 16,900 stock options in Arcus Biosciences, Inc.
Summary
- Director Patrick Machado was granted 5,700 restricted stock units (RSUs) on June 11, 2026.
- Director Patrick Machado was granted 16,900 stock options with an exercise price of $23.30 on June 11, 2026.
- Following these transactions, the director's total beneficial ownership of common stock is 44,300 shares.
- Both the RSUs and the stock options are scheduled to vest on the earlier of June 11, 2027, or the next annual meeting of stockholders.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure regarding director compensation that does not signal a change in company fundamentals.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Vesting schedule provides retention incentive for the director.
Negatives
- Issuance of equity awards results in potential future dilution for existing shareholders.
Risks
- Potential for share price volatility affecting the value of the granted options.
- Vesting acceleration clauses in the event of a change in control may influence future corporate strategy.
Future Outlook
The equity grants are subject to standard vesting conditions, aligning the director's long-term interests with the company's performance through June 2027.
Management Comments
- The grants are part of standard director compensation packages as indicated by the filing structure.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure long-term commitment and alignment with shareholder value creation.
Comparison to Industry Standards
- The use of RSUs and stock options for director compensation is consistent with standard practices for mid-cap biotechnology companies.
- Vesting periods of one year are common for annual director equity refreshers in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of equity to Director Patrick Machado. | 06/11/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Shareholders may experience minor dilution from the issuance of new equity.
Next Steps
- Vesting of equity awards on June 11, 2027, or the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 06/11/2026 | Date of the equity grant and earliest transaction. |
| 06/12/2026 | Date of filing. |
| 06/11/2027 | Vesting date for RSUs and stock options. |
| 06/10/2036 | Expiration date for the stock options. |
Keywords
Arcus Biosciences, RCUS, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.